Keros Therapeutics Inc (KROS)
14.89
-0.95
(-6.00%)
USD |
NASDAQ |
Jan 08, 16:00
14.75
-0.14
(-0.94%)
Pre-Market: 08:26
Keros Therapeutics SG&A Expense (Quarterly): 9.82M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Aptevo Therapeutics Inc | 2.11M |
| Corcept Therapeutics Inc | 73.74M |
| Regeneron Pharmaceuticals Inc | 714.40M |
| Scholar Rock Holding Corp | 16.06M |
| Trevi Therapeutics Inc | 2.863M |